{"data":[{"accessionNo":"0002052113-26-001128","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001664710","issuerName":"Keros Therapeutics, Inc.","ticker":"KROS","cusip":"492327101","securityClass":"Common Stock","eventDate":"2026-09-30","reportingPerson":"BlackRock Portfolio Management LLC","reportingCik":null,"personType":"HC","sharesOwned":1813870,"percentOfClass":9.1,"filedAt":"2026-10-27","canonicalUrl":"https://xoomar.com/markets/stocks/kros"},{"accessionNo":"0002012383-26-002890","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001664710","issuerName":"Keros Therapeutics, Inc.","ticker":"KROS","cusip":"492327101","securityClass":"Common Stock","eventDate":"2026-06-30","reportingPerson":"BlackRock, Inc.","reportingCik":null,"personType":"HC","sharesOwned":1671343,"percentOfClass":8.4,"filedAt":"2026-07-29","canonicalUrl":"https://xoomar.com/markets/stocks/kros"},{"accessionNo":"0002052113-26-000752","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001664710","issuerName":"Keros Therapeutics, Inc.","ticker":"KROS","cusip":"492327101","securityClass":"Common Stock","eventDate":"2026-06-30","reportingPerson":"BlackRock Portfolio Management LLC","reportingCik":null,"personType":"HC","sharesOwned":1122874,"percentOfClass":5.7,"filedAt":"2026-07-17","canonicalUrl":"https://xoomar.com/markets/stocks/kros"},{"accessionNo":"0001104659-26-062702","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001664710","issuerName":"Keros Therapeutics, Inc.","ticker":"KROS","cusip":"492327101","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-03-31","reportingPerson":"Daniel Mack","reportingCik":null,"personType":"HC","sharesOwned":1360419,"percentOfClass":6.9,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/kros"},{"accessionNo":"0001104659-26-062702","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001664710","issuerName":"Keros Therapeutics, Inc.","ticker":"KROS","cusip":"492327101","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-03-31","reportingPerson":"Wilmot B. Harkey","reportingCik":null,"personType":"HC","sharesOwned":1360419,"percentOfClass":6.9,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/kros"},{"accessionNo":"0001104659-26-062702","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001664710","issuerName":"Keros Therapeutics, Inc.","ticker":"KROS","cusip":"492327101","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-03-31","reportingPerson":"Nantahala Capital Management, LLC","reportingCik":null,"personType":"IA","sharesOwned":1360419,"percentOfClass":6.9,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/kros"},{"accessionNo":"0002012383-26-001069","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001664710","issuerName":"Keros Therapeutics, Inc.","ticker":"KROS","cusip":"492327101","securityClass":"Common Stock","eventDate":"2026-03-31","reportingPerson":"BlackRock, Inc.","reportingCik":null,"personType":"HC","sharesOwned":1990842,"percentOfClass":10.1,"filedAt":"2026-04-07","canonicalUrl":"https://xoomar.com/markets/stocks/kros"},{"accessionNo":"0000102909-26-001617","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001664710","issuerName":"Keros Therapeutics Inc","ticker":"KROS","cusip":"492327101","securityClass":"Common Stock","eventDate":"2026-03-13","reportingPerson":"The Vanguard Group","reportingCik":null,"personType":"IA","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-03-27","canonicalUrl":"https://xoomar.com/markets/stocks/kros"},{"accessionNo":"0001104659-26-016389","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001664710","issuerName":"Keros Therapeutics, Inc.","ticker":"KROS","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"D. E. Shaw & Co., L.P.","reportingCik":null,"personType":"IA,PN","sharesOwned":756156,"percentOfClass":3.9,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/kros"},{"accessionNo":"0001104659-26-016389","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001664710","issuerName":"Keros Therapeutics, Inc.","ticker":"KROS","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"D. E. Shaw & Co., L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":755473,"percentOfClass":3.9,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/kros"},{"accessionNo":"0001104659-26-016389","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001664710","issuerName":"Keros Therapeutics, Inc.","ticker":"KROS","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"David E. Shaw","reportingCik":null,"personType":"IN","sharesOwned":756156,"percentOfClass":3.9,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/kros"},{"accessionNo":"0001013594-26-000256","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001664710","issuerName":"Keros Therapeutics, Inc.","ticker":"KROS","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share (the \"Common Stock\")","eventDate":"2025-12-31","reportingPerson":"EMAI Management, LLC","reportingCik":null,"personType":"OO","sharesOwned":823707,"percentOfClass":2.7,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/kros"},{"accessionNo":"0001013594-26-000256","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001664710","issuerName":"Keros Therapeutics, Inc.","ticker":"KROS","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share (the \"Common Stock\")","eventDate":"2025-12-31","reportingPerson":"Madison Avenue International LP","reportingCik":null,"personType":"PN","sharesOwned":823707,"percentOfClass":2.7,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/kros"},{"accessionNo":"0001013594-26-000256","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001664710","issuerName":"Keros Therapeutics, Inc.","ticker":"KROS","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share (the \"Common Stock\")","eventDate":"2025-12-31","reportingPerson":"Madison Avenue Partners, LP","reportingCik":null,"personType":"PN","sharesOwned":823707,"percentOfClass":2.7,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/kros"},{"accessionNo":"0001013594-26-000256","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001664710","issuerName":"Keros Therapeutics, Inc.","ticker":"KROS","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share (the \"Common Stock\")","eventDate":"2025-12-31","reportingPerson":"Madison Avenue GP, LLC","reportingCik":null,"personType":"OO","sharesOwned":823707,"percentOfClass":2.7,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/kros"},{"accessionNo":"0001013594-26-000256","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001664710","issuerName":"Keros Therapeutics, Inc.","ticker":"KROS","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share (the \"Common Stock\")","eventDate":"2025-12-31","reportingPerson":"Caraway Jackson Investments LLC","reportingCik":null,"personType":"OO","sharesOwned":823707,"percentOfClass":2.7,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/kros"},{"accessionNo":"0001013594-26-000256","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001664710","issuerName":"Keros Therapeutics, Inc.","ticker":"KROS","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share (the \"Common Stock\")","eventDate":"2025-12-31","reportingPerson":"Eli Samaha","reportingCik":null,"personType":"IN","sharesOwned":823707,"percentOfClass":2.7,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/kros"},{"accessionNo":"0000905148-26-000905","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001664710","issuerName":"Keros Therapeutics, Inc.","ticker":"KROS","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"Michael Gelband","reportingCik":null,"personType":"IN,HC","sharesOwned":13360,"percentOfClass":0.04,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/kros"},{"accessionNo":"0000905148-26-000905","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001664710","issuerName":"Keros Therapeutics, Inc.","ticker":"KROS","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"ExodusPoint Capital Management, LP","reportingCik":null,"personType":"IA,PN","sharesOwned":13360,"percentOfClass":0.04,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/kros"},{"accessionNo":"0000905148-26-000905","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001664710","issuerName":"Keros Therapeutics, Inc.","ticker":"KROS","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"ExodusPoint Capital Partners GP, LLC","reportingCik":null,"personType":"CO,HC","sharesOwned":13360,"percentOfClass":0.04,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/kros"},{"accessionNo":"0001214659-26-002021","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001664710","issuerName":"Keros Therapeutics, Inc.","ticker":"KROS","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"TANG CAPITAL PARTNERS, LP","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/kros"},{"accessionNo":"0001214659-26-002021","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001664710","issuerName":"Keros Therapeutics, Inc.","ticker":"KROS","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"TANG CAPITAL PARTNERS INTERNATIONAL, LP","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/kros"},{"accessionNo":"0001214659-26-002021","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001664710","issuerName":"Keros Therapeutics, Inc.","ticker":"KROS","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"TANG CAPITAL PARTNERS III, INC","reportingCik":null,"personType":"CO","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/kros"},{"accessionNo":"0001214659-26-002021","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001664710","issuerName":"Keros Therapeutics, Inc.","ticker":"KROS","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"TANG CAPITAL PARTNERS IV, INC","reportingCik":null,"personType":"CO","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/kros"},{"accessionNo":"0001214659-26-002021","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001664710","issuerName":"Keros Therapeutics, Inc.","ticker":"KROS","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"TANG CAPITAL MANAGEMENT, LLC","reportingCik":null,"personType":"OO","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/kros"},{"accessionNo":"0001214659-26-002021","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001664710","issuerName":"Keros Therapeutics, Inc.","ticker":"KROS","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"KEVIN TANG","reportingCik":null,"personType":"IN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/kros"},{"accessionNo":"0000102909-26-000162","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001664710","issuerName":"Keros Therapeutics Inc","ticker":"KROS","cusip":null,"securityClass":"Common Stock","eventDate":"2025-12-31","reportingPerson":"The Vanguard Group","reportingCik":null,"personType":"IA","sharesOwned":1525355,"percentOfClass":5,"filedAt":"2026-01-30","canonicalUrl":"https://xoomar.com/markets/stocks/kros"},{"accessionNo":"0000905148-25-004126","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001664710","issuerName":"Keros Therapeutics, Inc.","ticker":"KROS","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-11-10","reportingPerson":"ExodusPoint Capital Partners GP, LLC","reportingCik":null,"personType":"CO,HC","sharesOwned":1907899,"percentOfClass":6.3,"filedAt":"2025-11-18","canonicalUrl":"https://xoomar.com/markets/stocks/kros"},{"accessionNo":"0000905148-25-004126","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001664710","issuerName":"Keros Therapeutics, Inc.","ticker":"KROS","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-11-10","reportingPerson":"Michael Gelband","reportingCik":null,"personType":"IN,HC","sharesOwned":1907899,"percentOfClass":6.3,"filedAt":"2025-11-18","canonicalUrl":"https://xoomar.com/markets/stocks/kros"},{"accessionNo":"0000905148-25-004126","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001664710","issuerName":"Keros Therapeutics, Inc.","ticker":"KROS","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-11-10","reportingPerson":"ExodusPoint Capital Management, LP","reportingCik":null,"personType":"IA,PN","sharesOwned":1907899,"percentOfClass":6.3,"filedAt":"2025-11-18","canonicalUrl":"https://xoomar.com/markets/stocks/kros"},{"accessionNo":"0001104659-25-102591","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001664710","issuerName":"Keros Therapeutics, Inc.","ticker":"KROS","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-10-20","reportingPerson":"David E. Shaw","reportingCik":null,"personType":"IN","sharesOwned":1545948,"percentOfClass":5.1,"filedAt":"2025-10-27","canonicalUrl":"https://xoomar.com/markets/stocks/kros"},{"accessionNo":"0001104659-25-102591","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001664710","issuerName":"Keros Therapeutics, Inc.","ticker":"KROS","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-10-20","reportingPerson":"D. E. Shaw & Co., L.P.","reportingCik":null,"personType":"IA,PN","sharesOwned":1545948,"percentOfClass":5.1,"filedAt":"2025-10-27","canonicalUrl":"https://xoomar.com/markets/stocks/kros"},{"accessionNo":"0001104659-25-102591","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001664710","issuerName":"Keros Therapeutics, Inc.","ticker":"KROS","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-10-20","reportingPerson":"D. E. Shaw & Co., L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":1537348,"percentOfClass":5,"filedAt":"2025-10-27","canonicalUrl":"https://xoomar.com/markets/stocks/kros"},{"accessionNo":"0001214659-25-015219","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001664710","issuerName":"Keros Therapeutics, Inc.","ticker":"KROS","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-10-15","reportingPerson":"TANG CAPITAL MANAGEMENT, LLC","reportingCik":null,"personType":"OO","sharesOwned":2418984,"percentOfClass":7.9,"filedAt":"2025-10-22","canonicalUrl":"https://xoomar.com/markets/stocks/kros"},{"accessionNo":"0001214659-25-015219","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001664710","issuerName":"Keros Therapeutics, Inc.","ticker":"KROS","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-10-15","reportingPerson":"KEVIN TANG","reportingCik":null,"personType":"IN","sharesOwned":2418984,"percentOfClass":7.9,"filedAt":"2025-10-22","canonicalUrl":"https://xoomar.com/markets/stocks/kros"},{"accessionNo":"0001214659-25-015219","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001664710","issuerName":"Keros Therapeutics, Inc.","ticker":"KROS","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-10-15","reportingPerson":"TANG CAPITAL PARTNERS, LP","reportingCik":null,"personType":"PN","sharesOwned":1579237,"percentOfClass":5.2,"filedAt":"2025-10-22","canonicalUrl":"https://xoomar.com/markets/stocks/kros"},{"accessionNo":"0001214659-25-015219","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001664710","issuerName":"Keros Therapeutics, Inc.","ticker":"KROS","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-10-15","reportingPerson":"TANG CAPITAL PARTNERS INTERNATIONAL, LP","reportingCik":null,"personType":"PN","sharesOwned":839747,"percentOfClass":2.7,"filedAt":"2025-10-22","canonicalUrl":"https://xoomar.com/markets/stocks/kros"},{"accessionNo":"0001214659-25-015219","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001664710","issuerName":"Keros Therapeutics, Inc.","ticker":"KROS","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-10-15","reportingPerson":"TANG CAPITAL PARTNERS III, INC","reportingCik":null,"personType":"CO","sharesOwned":0,"percentOfClass":0,"filedAt":"2025-10-22","canonicalUrl":"https://xoomar.com/markets/stocks/kros"},{"accessionNo":"0001214659-25-015219","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001664710","issuerName":"Keros Therapeutics, Inc.","ticker":"KROS","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-10-15","reportingPerson":"TANG CAPITAL PARTNERS IV, INC","reportingCik":null,"personType":"CO","sharesOwned":0,"percentOfClass":0,"filedAt":"2025-10-22","canonicalUrl":"https://xoomar.com/markets/stocks/kros"},{"accessionNo":"0000921895-25-002751","formType":"SCHEDULE 13D/A","amendmentNo":2,"issuerCik":"0001664710","issuerName":"Keros Therapeutics, Inc.","ticker":"KROS","cusip":null,"securityClass":"Common Stock, Par Value $0.0001 Per Share","eventDate":"2025-10-15","reportingPerson":"Pontifax Management 4 GP (2015) Ltd.","reportingCik":"0001726334","personType":"CO","sharesOwned":0,"percentOfClass":0,"filedAt":"2025-10-16","canonicalUrl":"https://xoomar.com/markets/stocks/kros"},{"accessionNo":"0000921895-25-002751","formType":"SCHEDULE 13D/A","amendmentNo":2,"issuerCik":"0001664710","issuerName":"Keros Therapeutics, Inc.","ticker":"KROS","cusip":null,"securityClass":"Common Stock, Par Value $0.0001 Per Share","eventDate":"2025-10-15","reportingPerson":"Pontifax (Israel) IV, L.P.","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2025-10-16","canonicalUrl":"https://xoomar.com/markets/stocks/kros"},{"accessionNo":"0000921895-25-002751","formType":"SCHEDULE 13D/A","amendmentNo":2,"issuerCik":"0001664710","issuerName":"Keros Therapeutics, Inc.","ticker":"KROS","cusip":null,"securityClass":"Common Stock, Par Value $0.0001 Per Share","eventDate":"2025-10-15","reportingPerson":"Pontifax (Cayman) IV, L.P.","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2025-10-16","canonicalUrl":"https://xoomar.com/markets/stocks/kros"},{"accessionNo":"0000921895-25-002751","formType":"SCHEDULE 13D/A","amendmentNo":2,"issuerCik":"0001664710","issuerName":"Keros Therapeutics, Inc.","ticker":"KROS","cusip":null,"securityClass":"Common Stock, Par Value $0.0001 Per Share","eventDate":"2025-10-15","reportingPerson":"Pontifax (China) IV, L.P.","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2025-10-16","canonicalUrl":"https://xoomar.com/markets/stocks/kros"},{"accessionNo":"0000921895-25-002751","formType":"SCHEDULE 13D/A","amendmentNo":2,"issuerCik":"0001664710","issuerName":"Keros Therapeutics, Inc.","ticker":"KROS","cusip":null,"securityClass":"Common Stock, Par Value $0.0001 Per Share","eventDate":"2025-10-15","reportingPerson":"Pontifax Late Stage Fund L.P.","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2025-10-16","canonicalUrl":"https://xoomar.com/markets/stocks/kros"},{"accessionNo":"0000921895-25-002751","formType":"SCHEDULE 13D/A","amendmentNo":2,"issuerCik":"0001664710","issuerName":"Keros Therapeutics, Inc.","ticker":"KROS","cusip":null,"securityClass":"Common Stock, Par Value $0.0001 Per Share","eventDate":"2025-10-15","reportingPerson":"Pontifax Late Stage GP Ltd.","reportingCik":null,"personType":"CO","sharesOwned":0,"percentOfClass":0,"filedAt":"2025-10-16","canonicalUrl":"https://xoomar.com/markets/stocks/kros"},{"accessionNo":"0000902664-25-004410","formType":"SCHEDULE 13D/A","amendmentNo":5,"issuerCik":"0001664710","issuerName":"Keros Therapeutics, Inc.","ticker":"KROS","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-10-15","reportingPerson":"ADAR1 Capital Management, LLC","reportingCik":"0001940272","personType":"OO","sharesOwned":0,"percentOfClass":0,"filedAt":"2025-10-15","canonicalUrl":"https://xoomar.com/markets/stocks/kros"},{"accessionNo":"0000902664-25-004410","formType":"SCHEDULE 13D/A","amendmentNo":5,"issuerCik":"0001664710","issuerName":"Keros Therapeutics, Inc.","ticker":"KROS","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-10-15","reportingPerson":"ADAR1 Capital Management GP, LLC","reportingCik":"0001940267","personType":"OO","sharesOwned":0,"percentOfClass":0,"filedAt":"2025-10-15","canonicalUrl":"https://xoomar.com/markets/stocks/kros"},{"accessionNo":"0000902664-25-004410","formType":"SCHEDULE 13D/A","amendmentNo":5,"issuerCik":"0001664710","issuerName":"Keros Therapeutics, Inc.","ticker":"KROS","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-10-15","reportingPerson":"Daniel Schneeberger","reportingCik":"0001861120","personType":"IN","sharesOwned":0,"percentOfClass":0,"filedAt":"2025-10-15","canonicalUrl":"https://xoomar.com/markets/stocks/kros"}],"updatedAt":"2026-11-03T22:37:59.898Z","source":"xoomar.com","docs":"https://xoomar.com/markets/api","license":"https://xoomar.com/terms","attribution":"Credit XOOMAR with a link to the dataset page on xoomar.com when you republish this data","canonicalUrl":"https://xoomar.com/markets/stocks/kros","meta":{"source":"SEC","sourceAttribution":"Schedule 13D and 13G data: SEC.","notice":"10 requests a minute without a key, 30 with a free key. Get a free key at https://xoomar.com/signup?utm_source=api, register your app at https://xoomar.com/developers/register?utm_source=api, and credit the data as \"Data: XOOMAR\" together with the sourceAttribution line."}}